ORGO — Organogenesis Holdings Share Price
0.000.00%
Last trade - 00:00- $669.79m
- $527.14m
- $482.04m
- 94
- 34
- 97
- 89
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 64.81 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -1.5% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.7 | ||
| Price to Tang. Book | 1.9 | ||
| Price to Free Cashflow | 160.39 | ||
| Price to Sales | 1.39 | ||
| EV to EBITDA | 33.48 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -0.31% | ||
| Return on Equity | -0.28% | ||
| Operating Margin | -0.27% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 338.3 | 468.06 | 450.89 | 433.14 | 482.04 | 488.25 | 549.3 | 13.06% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +427.84 | -82.42 | -61.01 | +107.31 | -63.96 | +339.47 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
Directors
- Gary Gillheeney PRE (66)
- David Francisco CFO (55)
- Patrick Bilbo COO (59)
- Lori Freedman VPR (54)
- Antonio Montecalvo VPR (55)
- Brian Grow OTH (45)
- Robert Ades DRC (47)
- David Erani DRC (32)
- Jon Giacomin DRC (54)
- Glenn Nussdorf DRC (66)
- Alan Ades IND (82)
- Prathyusha Duraibabu IND (42)
- Arthur Leibowitz IND (67)
- Wayne Mackie IND (72)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 10th, 2018
- Public Since
- December 2nd, 2016
- No. of Shareholders
- 585
- No. of Employees
- 869
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 126,853,536
- Address
- 85 Dan Rd, CANTON, 02021-2810
- Web
- https://investors.organogenesis.com
- Phone
- +1 7815750775
- Contact
- Mike Piccinino
- Auditors
- RSM US LLP
Upcoming Events for ORGO
Q1 2025 Organogenesis Holdings Inc Earnings Call
Organogenesis Holdings Inc Annual Shareholders Meeting
Q2 2025 Organogenesis Holdings Inc Earnings Release
Similar to ORGO
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Organogenesis Holdings share price?
As of Today at 22:29 UTC, shares in Organogenesis Holdings are trading at $5.28. This share price information is delayed by 15 minutes.
How has the Organogenesis Holdings share price performed this year?
Shares in Organogenesis Holdings last closed at $5.28 and the price had moved by +112.05% over the past 365 days. In terms of relative price strength the Organogenesis Holdings share price has outperformed the S&P500 Index by +91.21% over the past year.
What are the analyst and broker recommendations for Organogenesis Holdings?
The overall consensus recommendation for Organogenesis Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Organogenesis Holdings dividend yield?
Organogenesis Holdings does not currently pay a dividend.
Does Organogenesis Holdings pay a dividend?
Organogenesis Holdings does not currently pay a dividend.
When does Organogenesis Holdings next pay dividends?
Organogenesis Holdings does not currently pay a dividend.
How do I buy Organogenesis Holdings shares?
To buy shares in Organogenesis Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Organogenesis Holdings?
As of the previous close price of $5.28, shares in Organogenesis Holdings had a market capitalisation of $669.79m.
Where are Organogenesis Holdings shares listed?
Here are the trading details for Organogenesis Holdings:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ORGO
What kind of share is Organogenesis Holdings?
Based on an overall assessment of its quality, value and momentum Organogenesis Holdings is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Organogenesis Holdings share price forecast for 2025?
The analyst consensus target price for shares in Organogenesis Holdings is $6.00. That is 13.64% above the last closing price of $5.28.
Analysts covering Organogenesis Holdings currently have a consensus Earnings Per Share (EPS) forecast of $0.04 for the next financial year.
Find out moreWhat is the trend in the Organogenesis Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Organogenesis Holdings. Over the past six months, its share price has outperformed the S&P500 Index by +90.8%.
As of the last closing price of $5.28, shares in Organogenesis Holdings were trading +49.7% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Organogenesis Holdings PE Ratio?
The Organogenesis Holdings PE ratio based on its reported earnings over the past 12 months is 64.81. The shares last closed at $5.28.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Organogenesis Holdings?
Organogenesis Holdings' management team is headed by:
- Gary Gillheeney - PRE
- David Francisco - CFO
- Patrick Bilbo - COO
- Lori Freedman - VPR
- Antonio Montecalvo - VPR
- Brian Grow - OTH
- Robert Ades - DRC
- David Erani - DRC
- Jon Giacomin - DRC
- Glenn Nussdorf - DRC
- Alan Ades - IND
- Prathyusha Duraibabu - IND
- Arthur Leibowitz - IND
- Wayne Mackie - IND